Optimer gains 13% on positive FDA review of intestinal infection antibiotic
This article was originally published in Scrip
Executive Summary
US FDA drug reviewers appeared satisfied with the efficacy and safety of Optimer Pharmaceuticals' experimental oral antibiotic Dificid (fidaxomicin) in treating and preventing recurrences of Clostridium difficile infection (CDI), a disease that can cause serious diarrhea and other intestinal conditions, such as colitis, sometimes resulting in death.